AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36175821 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine weekly tapered to 0.01% atropine daily at 6 months
Number of subjects: 207
Study 36175821 — intervention group
Group type: COMPARATOR
Intervention: 0.01% atropine daily for 1 year
Number of subjects: 207
Study 36175848 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) at 1.0 - 1.5 mA for 20 minutes
Number of subjects: 10
Study 36175848 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (initial 30-second ramp up to 1.5 mA followed by a 30-second ramp down)
Number of subjects: 10
Study 36175848 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events survey, Box and Blocks Test (BBT) motor assessment, setup ease/comfort survey
Number of subjects: 10
Study 36175864 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT with high-intensity therapist training
Number of subjects: 1240
Study 36175864 — intervention group
Group type: COMPARATOR
Intervention: TF-CBT with low therapist and leadership training
Number of subjects: 1240
Study 36175864 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-CBT
Number of subjects: 1240
Study 36175948 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antimicrobial therapy for more than 72 hours
Number of subjects: 254
Study 36175948 — intervention group
Group type: COMPARATOR
Intervention: Narrow-spectrum antimicrobial therapy (less than 72 hours)
Number of subjects: 254
Study 36175948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular comorbidity on ICU admission
Number of subjects: 254
Study 36175978 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Scan Ultrasound System (ESUS)
Number of subjects: 50
Study 36175978 — intervention group
Group type: COMPARATOR
Intervention: Lens Opacity Classification System III (LOCS III, comparator)
Number of subjects: 50
Study 36175988 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD7 CAR T-cells
Number of subjects: 1
Study 36176043 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate brachytherapy (LDR-BT)
Number of subjects: 1241
Study 36176043 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 1241
Study 36176043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1241
Study 36176639 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of vitamin D
Number of subjects: 144
Study 36177053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative robotic radiosurgery (prRS) - single 21 Gy fraction
Number of subjects: 70
Study 36177306 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) training for 8 weeks
Number of subjects: 69
Study 36177306 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 69
Study 36177676 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 55
Study 36177835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 10000
Study 36177835 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 10000
Study 36177910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 2737
Study 36177910 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 2737
Study 36177913 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT-durvalumab
Number of subjects: 84
Study 36177913 — intervention group
Group type: COMPARATOR
Intervention: CCRT
Number of subjects: 84
Study 36178036 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36178134 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36178485 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (ongoing treatment with evolocumab 140 mg, n=632, 38.1% of total)
Number of subjects: 1659
Study 36178485 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (newly treated within 30 days before baseline visit)
Number of subjects: 1659
Study 36178485 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (ongoing treatment)
Number of subjects: 1659
Study 36178485 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9i receivers (both groups)
Number of subjects: 1659
Study 36178485 — intervention group
Group type: COMPARATOR
Intervention: Non-receivers
Number of subjects: 1659
Study 36178583 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment adherence after 1 year
Number of subjects: 763
Study 36178583 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment adherence after 7 years
Number of subjects: 763
Study 36178583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean change in BASDAI score for adherent patients at 1 year
Number of subjects: 763
Study 36178583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean change in BASFI score for adherent patients at 1 year
Number of subjects: 763
Study 36178584 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 150 mg administered subcutaneously (SC) at weeks 0, 4, and every 12 weeks thereafter
Number of subjects: 1527
Study 36178584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study 36178715 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Story Recall Task (ASRT)
Number of subjects: 200
Study 36179090 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable sensors during 1 week of unsupervised daily-living monitoring
Number of subjects: 28
Study 36179090 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home off-medication testing
Number of subjects: 28
Study 36179090 — intervention group
Group type: COMPARATOR
Intervention: Self-report questionnaires
Number of subjects: 28
Study 36179090 — intervention group
Group type: COMPARATOR
Intervention: In-home on-medication testing
Number of subjects: 28
Study 36179255 — intervention group
Group type: EXPERIMENTAL
Intervention: NOT-rule 1
Number of subjects: 4804
Study 36179255 — intervention group
Group type: EXPERIMENTAL
Intervention: NOT-rule 2
Number of subjects: 4804
Study 36179255 — intervention group
Group type: EXPERIMENTAL
Intervention: NOT-rule 3
Number of subjects: 4804
Study 36179255 — intervention group
Group type: EXPERIMENTAL
Intervention: NOT-rules overall
Number of subjects: 4804
Study 36179488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose and volume de-escalated intensity-modulated radiation therapy (IMRT) after two cycles of induction chemotherapy with docetaxel 60 mg/m².
Number of subjects: 131
Study 36179736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fexinidazole (1200 mg for 20-34 kg; 1800 mg for 35 kg or more) once per day for 4 days, followed by 600 mg or 1200 mg once per day for 6 days.
Number of subjects: 125
Study 36179736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fexinidazole
Number of subjects: 125
Study 36179758 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-guided screening
Number of subjects: 1003
Study 36179758 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1003
Study 36179808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke subjects
Number of subjects: 0
Study 36179808 — intervention group
Group type: COMPARATOR
Intervention: CVD controls
Number of subjects: 0
Study 36180086 — intervention group
Group type: EXPERIMENTAL
Intervention: M1a and M1b patients
Number of subjects: 2082
Study 36180086 — intervention group
Group type: COMPARATOR
Intervention: M1c with one to three organs
Number of subjects: 2082
Study 36180086 — intervention group
Group type: EXPERIMENTAL
Intervention: M1b-liver metastases
Number of subjects: 2082
Study 36180086 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (M1a, M1b-non-liver, M1c-1-3-orgsys-non-liver)
Number of subjects: 2082
Study 36180086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (M1c-liver, M1b-liver, M1c-4+-orgsys)
Number of subjects: 2082
Study 36180086 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender and Eastern Cooperative Oncology Group stage 0
Number of subjects: 2082
Study 36180086 — intervention group
Group type: EXPERIMENTAL
Intervention: T1- or N0-status
Number of subjects: 2082
Study 36180103 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel investigational treatments for COPD and asthma
Number of subjects: 0
Study 36180103 — intervention group
Group type: COMPARATOR
Intervention: Existing COPD and asthma treatments
Number of subjects: 0
Study 36180114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires for sleep disorders
Number of subjects: 46
Study 36180329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib monotherapy
Number of subjects: 12
Study 36180329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib plus rituximab
Number of subjects: 12
Study 36180329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (ixazomib monotherapy and ixazomib plus rituximab)
Number of subjects: 12
Study 36180379 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative RT
Number of subjects: 301
Study 36180379 — intervention group
Group type: COMPARATOR
Intervention: Palliative RT
Number of subjects: 301
Study 36180379 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of geriatric impairments
Number of subjects: 301
Study 36180844 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP) analysis of self-reported narratives
Number of subjects: 121
Study 36180844 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) algorithms for classification
Number of subjects: 121
Study 36180844 — intervention group
Group type: EXPERIMENTAL
Intervention: Thematic and sentiment analysis of text
Number of subjects: 121
Study 36180896 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network visualizations coupled with group Motivational Interviewing (MI)
Number of subjects: 91
Study 36180896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot workshop sessions with social network visualizations
Number of subjects: 91
Study 36181587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy group (CPT)
Number of subjects: 120
Study 36181587 — intervention group
Group type: COMPARATOR
Intervention: PTSD coping skills group (PCS)
Number of subjects: 120
Study 36181605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AI exposure (AI ratio < 0.40)
Number of subjects: 569
Study 36181605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate AI exposure (0.40 ≤ AI ratio ≤ 0.60)
Number of subjects: 569
Study 36181605 — intervention group
Group type: EXPERIMENTAL
Intervention: High AI exposure (AI ratio > 0.60)
Number of subjects: 569
Study 36181605 — intervention group
Group type: EXPERIMENTAL
Intervention: AI exposure (overall)
Number of subjects: 569
Study 36181952 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness intervention (VO2 measurement)
Number of subjects: 936
Study 36181952 — intervention group
Group type: COMPARATOR
Intervention: Control group (640 participants)
Number of subjects: 936
Study 36182027 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Number of subjects: 158
Study 36182027 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating attention control
Number of subjects: 158
Study 36182062 — intervention group
Group type: EXPERIMENTAL
Intervention: Posturography with vision suppression
Number of subjects: 95
Study 36182062 — intervention group
Group type: COMPARATOR
Intervention: Posturography without vision suppression
Number of subjects: 95
Study 36182062 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural Assessment Scale for Stroke
Number of subjects: 95
Study 36182805 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxalutamide 200 mg/day
Number of subjects: 45
Study 36182805 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxalutamide 200 mg/day in triple-negative subgroup
Number of subjects: 45
Study 36183064 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 80
Study 36183064 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen and CPAP outside ICU
Number of subjects: 80
Study 36183064 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV after 48 hours
Number of subjects: 80
Study 36183100 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly screening using ultrasensitive rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 340
Study 36183416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fieldworkers' reciprocity work during the MDA trial
Number of subjects: 0
Study 36183444 — intervention group
Group type: EXPERIMENTAL
Intervention: Arfolitixorin (30, 60, 120, or 240 mg/m) combined with 5-fluorouracil (5-FU)
Number of subjects: 105
Study 36183869 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to antibody testing
Number of subjects: 53207
Study 36183869 — intervention group
Group type: COMPARATOR
Intervention: Access to c-peptide or genetic testing
Number of subjects: 53207
Study 36184067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib (detailed dosage and duration not specified)
Number of subjects: 372
Study 36184067 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 372
Study 36184076 — intervention group
Group type: COMPARATOR
Intervention: Isotonic exercise training
Number of subjects: 579
Study 36184076 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise training
Number of subjects: 579
Study 36184076 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume isotonic exercise training
Number of subjects: 579
Study 36184192 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian stereotype method
Number of subjects: 0
Study 36184192 — intervention group
Group type: COMPARATOR
Intervention: Frequentist high-dimensional feature selection
Number of subjects: 0
Study 36184219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride dipsticks
Number of subjects: 0
Study 36184219 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine dipsticks
Number of subjects: 0
Study 36184219 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected creatinine values
Number of subjects: 0
Study 36184238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound meal accommodation test (UMAT) in Group A (without FI)
Number of subjects: 61
Study 36184238 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound meal accommodation test (UMAT) in Group B (with FI)
Number of subjects: 61
Study 36184294 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal portal vein flow pulsatility (PPF50) before CPB
Number of subjects: 373
Study 36184294 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal portal vein flow pulsatility (PPF50) after CPB
Number of subjects: 373
Study 36184301 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (two healthy diets)
Number of subjects: 540
Study 36184624 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 1068
Study 36184624 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 1068
Study 36184629 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia preceding general anaesthesia (SPA)
Number of subjects: 636
Study 36184629 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia alone (GA)
Number of subjects: 636
Study 36184642 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg + Apatinib 500 mg + Fuzuloparib 100 mg
Number of subjects: 32
Study 36184730 — intervention group
Group type: EXPERIMENTAL
Intervention: EG (EyeGuidance module)
Number of subjects: 60
Study 36184730 — intervention group
Group type: COMPARATOR
Intervention: Single image analysis
Number of subjects: 60
Study 36185070 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient screening colonoscopy
Number of subjects: 312
Study 36185311 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanotechnology-enhanced immunotherapy combined with ferroptosis; specific dosage and duration not mentioned.
Number of subjects: 0
Study 36185311 — intervention group
Group type: COMPARATOR
Intervention: Ferroptosis inducers; specific details not mentioned.
Number of subjects: 0
Study 36185330 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 36185388 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote implementation of the Goals for Reaching Optimal Wellness intervention
Number of subjects: 0
Study 36185388 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36185465 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A score (inflammation-based risk score)
Number of subjects: 3124
Study 36185465 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A score
Number of subjects: 3124
Study 36185653 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma fatty acid (PFA) levels in adults with moderate or severe COVID-19
Number of subjects: 0
Study 36185653 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid levels in adults with severe COVID-19
Number of subjects: 0
Study 36185653 — intervention group
Group type: EXPERIMENTAL
Intervention: Alterations in PFA profiles during COVID-19 infection
Number of subjects: 0
Study 36185653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acids as nutritional targets
Number of subjects: 0
Study 36185706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous difelikefalin 0.5 μg/kg after each hemodialysis session for 12 weeks
Number of subjects: 222
Study 36185772 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening (instrumental Western Classical music)
Number of subjects: 9
Study 36185772 — intervention group
Group type: COMPARATOR
Intervention: Nature sound control
Number of subjects: 9
Study 36185772 — intervention group
Group type: COMPARATOR
Intervention: No sound control
Number of subjects: 9
Study 36185969 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous vaccination (three doses of BNT162b2) followed by BNT162b2 booster
Number of subjects: 140
Study 36185969 — intervention group
Group type: COMPARATOR
Intervention: Heterologous vaccination (two doses of CoronaVac followed by BNT162b2 booster)
Number of subjects: 140
Study 36186606 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (n=91)
Number of subjects: 276
Study 36186606 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing/resistance exercise (n=92)
Number of subjects: 276
Study 36186606 — intervention group
Group type: COMPARATOR
Intervention: Control (n=93)
Number of subjects: 276
Study 36186648 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal COVID-19 infection
Number of subjects: 34
Study 36186648 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine administration to convalescent mothers
Number of subjects: 34
Study 36186648 — intervention group
Group type: COMPARATOR
Intervention: Healthy unrelated controls
Number of subjects: 34
Study 36186721 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (0.5-2.5 mg three times daily, based on bodyweight)
Number of subjects: 24
Study 36186721 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 24
Study 36186786 — intervention group
Group type: EXPERIMENTAL
Intervention: New biomarkers for TB outcome prediction
Number of subjects: 60
Study 36186786 — intervention group
Group type: COMPARATOR
Intervention: Latent TB infection (Control)
Number of subjects: 60
Study 36186794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 mL/kg
Number of subjects: 10
Study 36186794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 8 mL/kg
Number of subjects: 10
Study 36186794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 mL/kg
Number of subjects: 10
Study 36186794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 12 mL/kg
Number of subjects: 10
Study 36186800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet supplemented with ketoacids (LPD + KA)
Number of subjects: 58
Study 36186800 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-protein diet (LPD)
Number of subjects: 58
Study 36186810 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine ointment applied twice daily for 2 weeks
Number of subjects: 20
Study 36186856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy (Feel-Good intervention), 8 sessions over 8 weeks.
Number of subjects: 36
Study 36186962 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-arm systolic pressure difference (IASBPD)
Number of subjects: 320
Study 36186962 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstroke time (UT)
Number of subjects: 320
Study 36186962 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstroke time per cardiac cycle (UTCC)
Number of subjects: 320
Study 36186962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IASBPD and PVR-derived parameters
Number of subjects: 320
Study 36186982 — intervention group
Group type: COMPARATOR
Intervention: ≥5 live births
Number of subjects: 3454
Study 36186982 — intervention group
Group type: COMPARATOR
Intervention: 1-2 live births
Number of subjects: 3454
Study 36186982 — intervention group
Group type: COMPARATOR
Intervention: 3-4 live births
Number of subjects: 3454
Study 36186982 — intervention group
Group type: COMPARATOR
Intervention: 0 live births (nulliparity)
Number of subjects: 3454
Study 36187009 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 97
Study 36187555 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53-mutations
Number of subjects: 9104
Study 36187555 — intervention group
Group type: EXPERIMENTAL
Intervention: Any mutation in the 31 genes (mut31)
Number of subjects: 9104
Study 36187555 — intervention group
Group type: EXPERIMENTAL
Intervention: CDKN2A-deletion
Number of subjects: 9104
Study 36187555 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN-deletion
Number of subjects: 9104
Study 36187555 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC-amplification
Number of subjects: 9104
Study 36187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge™ assessment
Number of subjects: 0
Study 36187722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge™
Number of subjects: 0
Study 36187760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial-targeted antioxidant supplementation
Number of subjects: 0
Study 36187760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0